Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children | Zendy

H Green | Zendy; Diana M. Gibb | Zendy; Walker As | Zendy; Deenan Pillay | Zendy; Karina Butler | Zendy; Flora Candeias | Zendy; Guido Castelli Gattinara | Zendy; Alexandra Compagnucci | Zendy; Della Negra M | Zendy; Anita De Rossi | Zendy; Cornelia FeiternaSperling | Zendy; Carlo Giaquinto | Zendy; Lynda Harper | Zendy; J Lévy | Zendy; Y Saïdi | Zendy; Uwe Wintergerst | Zendy

Open Access

Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children

Author(s) -

H Green,

Diana M. Gibb,

Walker As,

Deenan Pillay,

Karina Butler,

Flora Candeias,

Guido Castelli Gattinara,

Alexandra Compagnucci,

Della Negra M,

Anita De Rossi,

Cornelia FeiternaSperling,

Carlo Giaquinto,

Lynda Harper,

J Lévy,

Y Saïdi,

Uwe Wintergerst

Publication year - 2007

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e3280e087e7

Subject(s) - lamivudine , abacavir , zidovudine , nelfinavir , medicine , reverse transcriptase inhibitor , virology , sida , viral load , human immunodeficiency virus (hiv) , viral disease , antiretroviral therapy , virus , hepatitis b virus

To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research